CDKN2A and breast carcinoma: The same trend could be observed between the predicted and existing data, which was shown in Figure 3B. Furthermore, PD-0332991, also named palbociclib, with 590 existing response values in cell lines in GDSC, is an effective drug in the treatment of several cancers including breast cancer, as a cyclin-dependent kinase 4/6 inhibitor.57, 58, 59 The CDKN2A mutation was selected to investigate its contribution to the PD-0332991 sensitivity.